| Price | $1.85 |
| Year Range | $1.12 – $2.51 |
| Market Cap | $52M |
| Industry | Biotechnology |
What Is INmune Bio’s AI Stock Analysis?
INmune Bio’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks INmune Bio’s momentum in near-real time.
INmune Bio (INMB) has an AltIndex AI Score of 45/100, currently a Hold signal. The AI Score distills INmune Bio's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
INmune Bio’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of INmune Bio — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving INMB’s AI Score?
Fundamentals
Revenue for the last quarter was $0. This is equal to the revenue of the quarter before it, showing stability. Also, this is equal to the revenue of the same quarter last year, indicating consistency. Net income for the last quarter was $-1.3M. This is an increase of -76.46% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of -94.80%, suggesting positive year-over-year growth. Ebitda for the last quarter was $-1.2M. This is an increase of -78.10% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of -85.44%, suggesting positive year-over-year growth.
See INmune Bio’s earnings and insider transactions.
Technicals
Today's stock price is $1.84. This represents a decrease of 17.12% compared to a month ago, which may be concerning in the short-term. Compared to a year ago, there is an increase of 0.55%, suggesting a positive long-term trend. The trend is bearish. The current SMA10 is $1.89, which is lower than the previous SMA10 of $1.90. This suggests a potential downward trend in price movement. The RSI is 50.9, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
The business outlook among employees at INmune Bio is low (an estimate of only 0% of employees have a positive outlook), a concerning sign. INmune Bio has an estimate of 1,000 visitors to their webpage. The number of visitors is down by -75% in the last couple of months, a worrisome trend as this can indicate a loss in customers.
Explore INmune Bio’s job postings, web traffic and app downloads.
Sentiment & social
Add to that that the sentiment is down by -33% in the last couple of weeks, an even more concerning trend. INmune Bio has 4,900 followers on their Twitter page. The number of followers is down by -1% in the last couple of months, indicating a loss in interest in the company.
Track INmune Bio’s market sentiment.
Frequently Asked Questions: INmune Bio AI Stock Analysis
INmune Bio's AltIndex AI Score is 45/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates INmune Bio a Hold (45/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of INmune Bio — company overview, fundamentals, technicals and alternative data, with a recommendation. See the INMB AI Score or sign up to read the full thesis.
